Replies to post #211419 on Biotech Values

[DewDiligence]

As of 3/31/17, 40mg Copaxone accounted for >85% of US Copaxone prescriptions, according to TEVA’s 1Q17 PR (http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&ID=2272193 ).

Is it possible the negative trend mostly reflects competition at 20mg?

No, the split between the branded and generic 20mg products has been pretty stable for several quarters.